Given that we have been away for a couple of weeks, this Bulletin is chock-full of news and analysis of recent events… This Week: Beckley Psytech Acquires Eleusis – Our Quick Analysis Empyrean Neuroscience Scoops $22m Series A to Genetically Engineer Small Molecule Therapeutics from Fungi and Plants DEA Increases Production Quotas for Psychedelics, Again Deep Dive: COMPASS Pathways Reveals Phase 3…


Previous articleSilo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
Next articleAlgernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study